TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05571514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mother-of-pearl
Description: The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation.
Study: NCT05848284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VDyne Transcatheter Tricuspid Valve Replacement System
Description: The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
Study: NCT05571514

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate is a source of calcium.
Study: NCT05740826

Intervention type: DEVICE
Intervention: Algometer
Description: The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain

Intervention type: DEVICE
Intervention: Algometer
Description: The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
Study: NCT06308926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001 (Low-dose)
Description: MRG-001 is subcutaneously administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001 (High-dose)
Description: MRG-001 is subcutaneously administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.
Study: NCT06669208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-005 CHIKV
Description: HydroVax-005 CHIKV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-005 CHIKV
Description: HydroVax-005 CHIKV vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9%, Normal Saline
Study: NCT06612151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride for injection
Description: Topotecan hydrochloride will be administered intravenously per prescribing information.
Study: NCT04792216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wild Salmon
Description: Wild salmon fillets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Farmed Salmon
Description: Farm salmon fillets
Study: NCT06497946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SlimTrack Plataform
Description: SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SlimTrack Plataform
Description: SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet prescription
Description: Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
Study: NCT05817279

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography
Description: Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography
Description: Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)
Study: NCT05522387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPro1595
Description: Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
Study: NCT04913766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus
Description: Five session psychological intervention focusing on problem management skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Mental health services provided by a mental health specialists according to their standard practices of care
Study: NCT04974918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of large Lip defects post traumatic or post tumor resection.
Description: A perforator near the defect was selected to accomplish a sufficient arc of rotation without tension. The flap was designed to cover the defect based on one perforator and to hide the donor site in the nasolabial fold. An incision on one side of the flap was made to the subcutaneous tissue. Undermining of the flap until the perforators were identified. After the perforators were identified, the flap was redesigned and an incision was made circumferentially. Dissection of the pedicle was performed until tension-free transposition was done to cover the defect, and the distal perforators were sacrificed to help flap movement.
Study: NCT05307731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guideline-based treatment for DM
Description: guideline-based treatment for DM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guideline-based treatment for DM
Description: guideline-based treatment for DM
Study: NCT05998278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Optimization of Systematic Prostate Biopsy
Description: Login the model based on our previous study (https://daringsky.shinyapps.io/prediction_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
Study: NCT05992571

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-OHB
Description: Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.
Study: NCT05086744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Iptacopan 200 mg BID
Study: NCT06259708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity focused ultrasound
Description: Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity focused ultrasound
Description: Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).
Study: NCT05109052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5505 and Atezolizumab and Bevacizumab
Description: Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
Study: NCT03622528

Intervention type: RADIATION
Intervention: Chest CT scan
Description: Standard dose chest CT scan
Study: NCT05914116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.
Study: NCT05922046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller on flat display
Description: The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller on flat display
Description: The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
Study: NCT04110262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dietary sodium intake
Description: Fourteen day feeding period of high dietary sodium (3400 mg/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dietary sodium intake
Description: Fourteen day feeding period of high dietary sodium (3400 mg/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dietary sodium intake
Description: Fourteen day feeding period of low dietary sodium (2300 mg/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dietary sodium intake
Description: Fourteen day feeding period of low dietary sodium (2300 mg/day)
Study: NCT05040386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPIC
Description: Participants randomized to the intervention arm receive usual COPD care + EPIC. EPIC is informed by the ENABLE model or early palliative care. ENABLE (Educate, Nurture, Advise, Before Life Ends) is a theory-based, rigorously tested, and multicomponent early palliative care model that improved quality of life and emotional symptoms in patients with advanced cancer. The PI adapted ENABLE to meet the specific needs of patients with COPD and their care partners through EPIC. EPIC includes a series of weekly telephone-based, nurse coach-led sessions for patients (six) and their care partners (four) aided by a manualized curriculum. Participants also complete activities geared to solving problems and making difficult decisions, attend a Supportive Care clinic visit, and complete advance directives.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual COPD Care
Description: Participants randomized to this arm receive standard of care for COPD. This includes routine clinic visits with their clinician, medications, inhalers, vaccinations, tobacco cessation counseling, illness education, cardiopulmonary rehabilitation, specialist referrals, and other COPD therapies deemed appropriate by their clinician.
Study: NCT05249192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate urinary catheter removal
Description: Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early urinary catheter removal
Description: urinary catheter removal on the first postoperative day (6 a.m)
Study: NCT04580225

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-Corner Arthrodesis
Description: Participants in Group A will receive a four-corner arthrodesis (fusion of the capitate, hamate, lunate, and triquetrum) with excision of the scaphoid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-Corner or Capitolunate Arthrodesis with Triquetral Excision
Description: Participants in Group B will receive a three-corner arthrodesis (fusion of the capitate, hamate, and lunate) or capitolunate arthrodesis (fusion of the capitate and lunate) with excision of the scaphoid and triquetrum.
Study: NCT06408259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Specified dose on specified days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05471479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Activated charcoal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No activated charcoal
Description: No activated charcoal
Study: NCT06496139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behavioural therapy
Description: The intervention consists of 8 weeks of therapist-guided self-help ICBT.
Study: NCT04751396

Intervention type: OTHER
Intervention: Best Practice
Description: Receive standard educational information
Study: NCT06335758

Intervention type: DEVICE
Intervention: Use of ReX to dispense and monitor solid oral medication therapy.
Description: ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
Study: NCT04751396

Intervention type: OTHER
Intervention: Educational Intervention
Description: Navigate educational tool

Intervention type: OTHER
Intervention: Educational Intervention
Description: Navigate educational tool

Intervention type: OTHER
Intervention: Interview
Description: Participate in interview
Study: NCT05518513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: adductor canal block with 0.25% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: adductor canal block with 0.25% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: adductor canal block with 0.25% bupivacaine
Study: NCT05049629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimera
Description: A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylo-Vision
Description: Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)
Study: NCT04683497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Intraoperative Ultrasound
Description: Intraoperative ultrasound with the administration of a contrast agent I.V.
Study: NCT06233955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level laser therapy
Description: is a non-invasive light source treatment that generates a single wavelength of light. It emits no heat, sound, or vibration. It is also called photobiology or bio-stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level laser therapy
Description: is a non-invasive light source treatment that generates a single wavelength of light. It emits no heat, sound, or vibration. It is also called photobiology or bio-stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland mobilization technique
Description: is a process of examination; assessment and treatment of musculoskeletal disorders by manipulative physiotherapy where a chain of oscillatory joint mobilization grades based on the pathological limit of tissue are used
Study: NCT04751396

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT05926804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 14 days of Lansoprazole (30 mg BID) (days 1-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 7 days of Amoxicillin (1000 mg BID) (days 1-7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 7 days of Clarithromycin (500 mg BID) (days 8-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 7 days of Metronidazole (500 mg BID) (days 8-14)
Study: NCT04700111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DOT Pattern
Description: DOT Pattern Spectacle Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Spectacles
Description: Control lens
Study: NCT05355402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
Study: NCT05506904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extubation Advisor
Description: Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. The clinical outcome case report form will be completed at the time of hospital discharge.
Study: NCT04793776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manage Emotions to Reduce Aggression
Description: MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Psychotherapy
Description: PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
Study: NCT05639933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-001 2% Topical Gel
Description: Topical gel, 2% active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-001 2% Topical Gel
Description: Topical gel, 2% active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-001 1% Topical Gel
Description: Topical gel, 1% active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-001 0.5% Topical Gel
Description: Topical gel, 0.5% active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-001 Placebo
Description: Topical gel, vehicle gel